Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | TACR2 | P21452 | 1/20 | 0.42 |
| ▸ | MC5R | P33032 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | MC3R | P41968 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7619723 | 0.95 | MMP1 (0.41) | MMP1EGFRFYNCHRM2CYP3A4 | |
| SCHEMBL6056388 | 0.85 | — | — | |
| SCHEMBL8395616 | 0.83 | FNTB (0.48) | EGFRFYNCHRM2CYP3A4ADRA2A | |
| SCHEMBL5891478 | 0.82 | EGFR (0.55) | EGFRFYNCHRM2CYP3A4ADRA2A | |
| SCHEMBL9182362 | 0.82 | EGFR (0.55) | EGFRFYNCHRM2CYP3A4ADRA2A | |
| SCHEMBL6056513 | 0.81 | FNTB (0.39) | EGFRFYNCHRM2CYP3A4ADRA2A | |
| SCHEMBL8399440 | 0.81 | — | — | |
| SCHEMBL14537266 | 0.81 | — | — | |
| SCHEMBL7619698 | 0.80 | CAPN1 (0.35) | — | |
| SCHEMBL9437492 | 0.79 | SCN9A (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0836383-A1 | COMBINATIONS OF INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-04-22 | — | — | EP | claimed |
| WO-1997001275-A1 | COMBINATIONS OF INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-01-16 | — | — | WO | claimed |
| EP-0535730-A2 | Inhibitors of farnesyl protein transferase | MERCK & CO. INC. (US) | 1993-04-07 | — | — | EP | claimed |
| WO-2006017369-A2 | USE OF A FARNESYL TRANSFERASE INHIBITOR IN THE TREATMENT OF VIRAL INFECTIONS | GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-02-16 | — | — | WO | disclosed |
| US-6160015-A | ADMINISTERING TO MAMMAL A FARNESYL PROTEIN TRANSFERASE INHIBITOR | UNIVERSITY OF CINCINNATI (US) | 2000-12-12 | — | — | US | disclosed |
| EP-0840605-A4 | COMPOUNDS USEFUL IN THE TREATMENT OF NEUROFIBROMATOSIS | UNIV CINCINNATI (US) | 2000-05-10 | — | — | EP | disclosed |
| WO-1998057654-A1 | METHODS FOR TREATMENT OF OCULAR NEOVASCULARIZATION | JOHNS HOPKINS UNIVERSITY (US) | 1998-12-23 | — | — | WO | disclosed |
| EP-0840605-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF NEUROFIBROMATOSIS | University of Cincinnati (US) | 1998-05-13 | — | — | EP | disclosed |
| EP-0836383-A1 | COMBINATIONS OF INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-04-22 | — | — | EP | disclosed |
| WO-1997002817-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF NEUROFIBROMATOSIS | UNIVERSITY OF CINCINNATI (US) | 1997-01-30 | — | — | WO | disclosed |
| WO-1997001275-A1 | COMBINATIONS OF INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-01-16 | — | — | WO | disclosed |
| US-5480893-A | ANTITUMOR | MERCK & CO., INC. (US) | 1996-01-02 | — | — | US | disclosed |
| US-5340828-A | Anticarcinogenic agents | MERCK & CO., INC. (US) | 1994-08-23 | — | — | US | disclosed |
| EP-0535730-A2 | Inhibitors of farnesyl protein transferase | MERCK & CO. INC. (US) | 1993-04-07 | — | — | EP | disclosed |